Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9BR39
UPID:
JPH2_HUMAN
Alternative names:
Junctophilin type 2
Alternative UPACC:
Q9BR39; E1P5X1; O95913; Q5JY74; Q9UJN4
Background:
Junctophilin-2, alternatively known as Junctophilin type 2, plays a pivotal role in cardiac muscle cells by bridging the plasma membrane and the sarcoplasmic reticulum. This protein is essential for normal excitation-contraction coupling, a process critical for heartbeats, by maintaining the optimal distance between membranes for calcium ion signaling. Its function extends to skeletal muscle, where it contributes to the structure of triad junctions.
Therapeutic significance:
Junctophilin-2 is implicated in serious heart conditions such as familial hypertrophic cardiomyopathy and dilated cardiomyopathy. These diseases, characterized by heart muscle dysfunction, highlight the protein's potential as a target for therapeutic intervention. Understanding Junctophilin-2's role could lead to breakthroughs in treating heart disease, offering hope for patients with these genetic disorders.